Regulatory Approval

Ionis targets a 2026 launch for zilganersen, its first neurology drug filing

The Phase 3 trial behind the Alexander disease therapy finished enrollment at 54 patients after a target cut from 73, with Ionis still guiding to an NDA filing and launch this year.

By AppliedXLJuly 13, 2026Trial NCT04849741

Executive Summary

Ionis has guided to a zilganersen filing and launch in Alexander disease this year, which would be its first independent commercial launch from its own neurology programs.
The registrational trial behind the filing has already completed its primary analysis; enrollment settled below its original target as the study moved from recruiting to fully enrolled over several years.
No other company has advanced a treatment into human testing for this specific genetic target in this disease, so the filing rests on a single dataset without a same-mechanism comparator.
Multiple rare-disease designations already support fast-tracked review, though the FDA has not stated a submission or decision date.

The guidance

Ionis Pharmaceuticals told investors in a January 12, 2026 update that it expects a "planned NDA submission in Q1 2026 and launch later this year" for zilganersen (ION373) in Alexander disease, describing it as "the first and only investigational medicine to demonstrate clinically meaningful and disease-modifying impact" in the condition. The company said it received Breakthrough Therapy designation for the program and has run a U.S. Expanded Access Program while preparing the filing. Chief executive Brett P. Monia called it "Ionis' first independent launch from our leading neurology pipeline". Ionis

The trial behind it

The claim rests on NCT04849741, a Phase 3 study testing zilganersen against a primary endpoint of percent change from baseline on the 10-Meter Walk Test, a measure of ambulatory function in Alexander disease. The trial enrolled patients with a documented GFAP gene mutation, moved to Active, not recruiting status in July 2025, and reached a primary completion date of August 22, 2025. No results have been posted to ClinicalTrials.gov as of this writing. NCT04849741

Enrollment and timeline moves

The trial's enrollment history shows a target that grew from 58 to 73 patients in November 2022, then settled at 54 actual enrolled when the study closed to new patients in July 2025, a reduction from the higher target as the study moved from active recruitment to a fixed cohort. The primary completion date moved three times since the trial opened in 2021, from February 2024 to March 2025, then September 2025, before settling at August 22, 2025, a total slip of about a year and a half from the original target. That kind of repeated timeline slippage before eventual completion is common in a rare, small-population disease where recruitment against a defined genetic mutation is slow. NCT04849741

The competitive field

No other industry-sponsored trial targets GFAP mRNA in Alexander disease with a therapy in human testing; the only comparator identified shares the same drug and sponsor as the pivotal trial itself. Other RNase H-recruiting oligonucleotides from Ionis and peers, including tofersen for ALS and bepirovirsen for hepatitis B, use the same mechanism class in different diseases and different targets, so they inform manufacturing and safety experience with the modality without serving as clinical precedent for this indication. Alexander disease itself has no FDA-approved disease-modifying treatment, so the filing would be the first regulatory decision of its kind for this target-indication pair.

Regulatory groundwork

Zilganersen holds Orphan Drug designation from both the FDA and the European Medicines Agency, granted in 2019 and 2020, along with FDA Rare Pediatric Disease designation from 2020, on top of the Breakthrough Therapy designation Ionis cited in January. Those designations support an accelerated review pathway once a filing is submitted, but the FDA has not disclosed a submission date, an application type, or a decision date for zilganersen.

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.